Literature DB >> 1831800

Tumor progression in human malignant melanoma is associated with changes in alpha 6/beta 1 laminin receptor.

P G Natali1, M R Nicotra, R Cavaliere, D Giannarelli, A Bigotti.   

Abstract

Cells of the melanocytic lineage have been shown to be capable of producing laminin and to lose this property during transformation. In the present study, we have evaluated immunohistochemically whether these changes are paralleled by an altered expression of the alpha 6/beta 1 laminin receptor. Results of this analysis have shown that while nevic cells display high levels of the receptor, this heterodimer undergoes a progressive decrease in expression in cutaneous melanomas of increasing invasiveness. A loss or unco-ordinated expression of the alpha 1/beta complex is present in the majority of the metastatic foci at different body sites. The present results show that during transformation the alpha 6/beta 1 laminin receptor undergoes quantitative alterations and deregulated expression of the 2 subunits. Although the functional relevance of these changes remains unknown, their occurrence in association with modifications of other cellular and extracellular macromolecules associated with tumor progression, strongly suggests a role in human melanoma progression.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1831800     DOI: 10.1002/ijc.2910490203

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Expression of VLA-2, VLA-3, and alpha(v) integrin receptors in uveal melanoma: association with microvascular architecture of the tumour and prognostic value.

Authors:  G Anastassiou; H Schilling; S Djakovic; N Bornfeld
Journal:  Br J Ophthalmol       Date:  2000-08       Impact factor: 4.638

2.  Characterization of integrin receptors in normal and neoplastic human brain.

Authors:  W Paulus; I Baur; D Schuppan; W Roggendorf
Journal:  Am J Pathol       Date:  1993-07       Impact factor: 4.307

3.  Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma.

Authors:  Bonnie E Gould Rothberg; David L Rimm
Journal:  J Invest Dermatol       Date:  2010-06-17       Impact factor: 8.551

4.  Expression of beta 1 integrins in non-neoplastic mammary epithelium, fibroadenoma and carcinoma of the breast.

Authors:  G Mechtersheimer; M Munk; T Barth; K Koretz; P Möller
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

5.  In situ expression of beta 1, beta 3 and beta 4 integrin subunits in non-neoplastic endothelium and vascular tumours.

Authors:  G Mechtersheimer; T Barth; W Hartschuh; T Lehnert; P Möller
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

6.  Comparative analysis of integrins in vitro and in vivo in uveal and cutaneous melanomas.

Authors:  J F Marshall; D C Rutherford; L Happerfield; A Hanby; A C McCartney; J Newton-Bishop; I R Hart
Journal:  Br J Cancer       Date:  1998-02       Impact factor: 7.640

7.  Expression level of integrin alpha 5 on tumour cells affects the rate of metastasis to the kidney.

Authors:  N Tani; S Higashiyama; N Kawaguchi; J Madarame; I Ota; Y Ito; Y Ohoka; S Shiosaka; Y Takada; N Matsuura
Journal:  Br J Cancer       Date:  2003-01-27       Impact factor: 7.640

Review 8.  Influence of Tumor Microenvironment and Fibroblast Population Plasticity on Melanoma Growth, Therapy Resistance and Immunoescape.

Authors:  Veronica Romano; Immacolata Belviso; Alessandro Venuta; Maria Rosaria Ruocco; Stefania Masone; Federica Aliotta; Giuseppe Fiume; Stefania Montagnani; Angelica Avagliano; Alessandro Arcucci
Journal:  Int J Mol Sci       Date:  2021-05-17       Impact factor: 5.923

9.  Beta1-6 branching of cell surface glycoproteins may contribute to uveal melanoma progression by up-regulating cell motility.

Authors:  Małgorzata Przybyło; Ewa Pocheć; Paweł Link-Lenczowski; Anna Lityńska
Journal:  Mol Vis       Date:  2008-03-26       Impact factor: 2.367

10.  Changes in expression of alpha 6/beta 4 integrin heterodimer in primary and metastatic breast cancer.

Authors:  P G Natali; M R Nicotra; C Botti; M Mottolese; A Bigotti; O Segatto
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.